SCHEMBL21747434

SCHEMBL21747434

NNC(=O)CNc1ccc(O)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.50
GAA P10253 3/20 0.50
MAPK1 P28482 3/20 0.50
BLM P54132 3/20 0.50
CYP3A4 P08684 2/20 0.50
GFER P55789 2/20 0.50
HIF1A Q16665 2/20 0.50
MPO P05164 1/20 0.50
KDM5A P29375 1/20 0.50
PMP22 Q01453 1/20 0.50
PEPD P12955 1/20 0.45
MGLL Q99685 1/20 0.45
ERCC1 P07992 1/20 0.44
ERCC4 Q92889 1/20 0.44
CYP1A1 P04798 2/20 0.43
CA1 P00915 4/20 0.41
CA2 P00918 4/20 0.41
MEN1 O00255 3/20 0.41
MAPT P10636 3/20 0.41
KMT2A Q03164 3/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2321477 0.82 MAPT (0.54) ALDH1A1GAAMGLLCA1CA2
SCHEMBL2319538 0.82 CA12 (0.52) ALDH1A1GAAMGLLCA1CA2
SCHEMBL5443604 0.82 CA12 (0.52) ALDH1A1GAAMGLLCA1CA2
SCHEMBL2318554 0.82 L3MBTL1 (0.58) ALDH1A1GAACYP3A4MGLLERCC1
SCHEMBL8621971 0.80 ALDH1A1 (0.45) ALDH1A1GAAMAPK1BLMCYP3A4
SCHEMBL9364440 0.80 PEPD (0.45) ALDH1A1GAAMAPK1BLMCYP3A4
SCHEMBL3659518 0.79 PEPD (0.54) ALDH1A1GAAMAPK1BLMCYP3A4
SCHEMBL5438871 0.78 CA1 (0.56) ALDH1A1GAAGFERMGLLCA1
SCHEMBL21834459 0.78 ALDH1A1 (0.51) ALDH1A1GAACYP3A4ERCC1ERCC4
SCHEMBL30366829 0.78 CA1 (0.56) ALDH1A1CA1CA2MEN1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12312371-B2 Optically-active 2-amino-phosphonoalkane acid, optically-active 2-amino-phosphonoalkane acid salt, and hydrates of these NAHLS CORPORATION CO., LTD. (JP) 2025-05-27 US claimed
EP-3613750-B1 OPTICALLY-ACTIVE 2-AMINO-PHOSPHONOALKANE ACID, OPTICALLY-ACTIVE 2-AMINO-PHOSPHONOALKANE ACID SALT, AND HYDRATES OF THESE UNIV KYOTO (JP) 2024-12-11 EP claimed
CN-110520432-B Optically active 2-amino-phosphonoalkanoic acid, optically active 2-amino-phosphonoalkanoic acid salt and hydrate thereof 株式会社NAHLS 2022-08-02 CN claimed
US-11220521-B2 Optically-active 2-amino-phosphonoalkane acid, optically-active 2-amino-phosphonoalkane acid salt, and hydrates of these NAHLS CORPORATION CO., LTD. (JP) 2022-01-11 US claimed
US-20200131207-A1 OPTICALLY-ACTIVE 2-AMINO-PHOSPHONOALKANE ACID, OPTICALLY-ACTIVE 2-AMINOPHOSPHONOALKANE ACID SALT, AND HYDRATES OF THESE NAHLS CORPORATION CO., LTD. (JP) 2020-04-30 US claimed
EP-3613750-A1 OPTICALLY-ACTIVE 2-AMINO-PHOSPHONOALKANE ACID, OPTICALLY-ACTIVE 2-AMINO-PHOSPHONOALKANE ACID SALT, AND HYDRATES OF THESE Kyoto University (JP) 2020-02-26 EP claimed
US-12312371-B2 Optically-active 2-amino-phosphonoalkane acid, optically-active 2-amino-phosphonoalkane acid salt, and hydrates of these NAHLS CORPORATION CO., LTD. (JP) 2025-05-27 US disclosed
EP-3613750-B1 OPTICALLY-ACTIVE 2-AMINO-PHOSPHONOALKANE ACID, OPTICALLY-ACTIVE 2-AMINO-PHOSPHONOALKANE ACID SALT, AND HYDRATES OF THESE UNIV KYOTO (JP) 2024-12-11 EP disclosed
EP-3656847-B1 ADDITIVE COMPOSITION FOR CULTURE MEDIUM, ADDITIVE COMPOUND FOR CULTURE MEDIUM, AND METHOD FOR CULTURE OF CELLS OR TISSUE USING SAME NISSAN CHEMICAL CORP (JP) 2022-08-17 EP disclosed
CN-110520432-B Optically active 2-amino-phosphonoalkanoic acid, optically active 2-amino-phosphonoalkanoic acid salt and hydrate thereof 株式会社NAHLS 2022-08-02 CN disclosed
US-20220135603-A1 OPTICALLY-ACTIVE 2-AMINO-PHOSPHONOALKANE ACID, OPTICALLY-ACTIVE 2-AMINO-PHOSPHONOALKANE ACID SALT, AND HYDRATES OF THESE NAHLS CORPORATION CO., LTD. (JP) 2022-05-05 US disclosed
US-11220521-B2 Optically-active 2-amino-phosphonoalkane acid, optically-active 2-amino-phosphonoalkane acid salt, and hydrates of these NAHLS CORPORATION CO., LTD. (JP) 2022-01-11 US disclosed
US-20210253518-A1 KINASE INHIBITOR NISSAN CHEMICAL CORPORATION (JP) 2021-08-19 US disclosed
EP-3804707-A1 KINASE INHIBITOR Nissan Chemical Corporation (JP) 2021-04-14 EP disclosed
US-20200165194-A1 ADDITIVE COMPOSITION FOR CULTURE MEDIUM, ADDITIVE COMPOUND FOR CULTURE MEDIUM, AND METHOD FOR CULTURE OF CELLS OR TISSUE USING SAME NISSAN CHEMICAL CORPORATION (JP) 2020-05-28 US disclosed
US-20200165194-A1 ADDITIVE COMPOSITION FOR CULTURE MEDIUM, ADDITIVE COMPOUND FOR CULTURE MEDIUM, AND METHOD FOR CULTURE OF CELLS OR TISSUE USING SAME NISSAN CHEMICAL CORPORATION (JP) 2020-05-28 US disclosed
EP-3656847-A1 ADDITIVE COMPOSITION FOR CULTURE MEDIUM, ADDITIVE COMPOUND FOR CULTURE MEDIUM, AND METHOD FOR CULTURE OF CELLS OR TISSUE USING SAME Nissan Chemical Corporation (JP) 2020-05-27 EP disclosed
US-20200131207-A1 OPTICALLY-ACTIVE 2-AMINO-PHOSPHONOALKANE ACID, OPTICALLY-ACTIVE 2-AMINOPHOSPHONOALKANE ACID SALT, AND HYDRATES OF THESE NAHLS CORPORATION CO., LTD. (JP) 2020-04-30 US disclosed
CN-110945118-A Composition for adding medium, compound for adding medium, and method for culturing cell or tissue using same 日产化学株式会社 2020-03-31 CN disclosed
EP-3613750-A1 OPTICALLY-ACTIVE 2-AMINO-PHOSPHONOALKANE ACID, OPTICALLY-ACTIVE 2-AMINO-PHOSPHONOALKANE ACID SALT, AND HYDRATES OF THESE Kyoto University (JP) 2020-02-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220135603-A1 OPTICALLY-ACTIVE 2-AMINO-PHOSPHONOALKANE ACID, OPTICALLY-ACTIVE 2-AMINO-PHOSPHONOALKANE ACID SALT, AND HYDRATES OF THESE AASDHPPT, PHYKPL, PKD2 ALDH1A1 255/4885GAA 2256/4885MAPK1 718/4885
US-11220521-B2 Optically-active 2-amino-phosphonoalkane acid, optically-active 2-amino-phosphonoalkane acid salt, and hydrates of these AASDHPPT, PHYKPL, PKD2 ALDH1A1 255/4885GAA 2256/4885MAPK1 718/4885
US-20200131207-A1 OPTICALLY-ACTIVE 2-AMINO-PHOSPHONOALKANE ACID, OPTICALLY-ACTIVE 2-AMINOPHOSPHONOALKANE ACID SALT, AND HYDRATES OF THESE AASDHPPT, PHYKPL, PHOSPHO1 ALDH1A1 407/4885GAA 2164/4885MAPK1 829/4885
US-20210253518-A1 KINASE INHIBITOR LATS2, LATS1, MAP3K6 ALDH1A1 3653/4885GAA 1811/4885MAPK1 38/4885
US-20200165194-A1 ADDITIVE COMPOSITION FOR CULTURE MEDIUM, ADDITIVE COMPOUND FOR CULTURE MEDIUM, AND METHOD FOR CULTURE OF CELLS OR TISSUE USING SAME NEFM, FGF2, FGF1 ALDH1A1 1259/4885GAA 4524/4885MAPK1 289/4885
US-12312371-B2 Optically-active 2-amino-phosphonoalkane acid, optically-active 2-amino-phosphonoalkane acid salt, and hydrates of these AASDHPPT, PHYKPL, PKD2 ALDH1A1 255/4885GAA 2256/4885MAPK1 718/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.